Navigation Links
Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
Date:8/19/2007

tients and only by healthcare professionals who are knowledgeable of and skilled in the use of Schedule II opioids to treat cancer pain.

The concomitant use of FENTORA with strong and moderate cytochrome P450 3A4 inhibitors may result in an increase in fentanyl plasma concentrations, and may cause potentially fatal respiratory depression.

Full prescribing information about FENTORA, including boxed warning, is available from http://www.FENTORA.com.

About Cephalon, Inc.

Founded in 1987, Cephalon, Inc. is an international biopharmaceutical company dedicated to the discovery, development and marketing of innovative products in four core therapeutic areas: central nervous system, pain, oncology and addiction. Cephalon has delivered a seven-year compound annual growth rate (CAGR) through 2006 greater than 75 percent and 2006 revenue of $1.760 billion. A member of the Fortune 1000, Cephalon currently employs approximately 3,000 people in the United States and Europe. U.S. sites include the company's headquarters in Frazer, Pennsylvania, and offices, laboratories or manufacturing facilities in West Chester, Pennsylvania, Salt Lake City, Utah, and suburban Minneapolis, Minnesota. Cephalon's European headquarters are located in Maisons-Alfort, France.

The company's proprietary products in the United States include: PROVIGIL(R) (modafinil) Tablets [C-IV], FENTORA, TRISENOX(R) (arsenic trioxide) injection, VIVITROL(R) (naltrexone for extended-release injectable suspension), GABITRIL(R) (tiagabine hydrochloride), NUVIGIL(TM) (armodafinil) Tablets [C-IV] and ACTIQ(R) (oral transmucosal fentanyl citrate) [C-II]. The company also markets numerous products internationally. Full prescribing information on its U.S. products is available at http://www.cephalon.com or by calling 1-800-896-5855.

In addition to historical facts or statements of current
'/>"/>

SOURCE Cephalon, Inc.

Copyright©2007 PR Newswire.

Page: 1 2 3 4 5

Related medicine technology :

1. Cephalon Presents Positive Results for Fentora in Breakthrough Pain Associated with Neuropathic Conditions
2. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
3. Sygnis Pharma AG announces date for presentation of clinical results
4. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
5. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
6. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
7. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
8. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
9. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
10. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
11. Protox Announces Positive Clinical Data from Prostate Cancer Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/2/2015)... , Aug. 3, 2015  Isis Pharmaceuticals, ... announced a strategic collaboration to discover and develop ... The new collaboration builds on a broad existing ... strategic approach in these therapeutic areas using novel ... extend use of its antisense technology to diseases ...
(Date:7/31/2015)... 2015  In today,s ever-changing marketplace, call centers must ... increasingly connected, and increasingly impatient with slow service. The ... channels and tools is driving call centers to explore ... According to research by benchmarking firm, Best Practices, ... in a call center study realize the impact of ...
(Date:7/31/2015)... 2015 RnRMarketResearch.com adds Syringes ... report that provides an overview of syringes and ... from in-house databases, secondary and primary research. ... products pipeline spread across 124 pages, talking about ... and 5 figures is now available at ...
Breaking Medicine Technology:AstraZeneca and Isis Pharmaceuticals to Discover and Develop Antisense Drugs for Cardiovascular, Metabolic and Renal Diseases 2AstraZeneca and Isis Pharmaceuticals to Discover and Develop Antisense Drugs for Cardiovascular, Metabolic and Renal Diseases 3AstraZeneca and Isis Pharmaceuticals to Discover and Develop Antisense Drugs for Cardiovascular, Metabolic and Renal Diseases 4Best Practices in Building World-Class Consumer & Over-the-Counter Call Centers 2Syringes and Needles Market Products Pipeline Review 2015 Report 2Syringes and Needles Market Products Pipeline Review 2015 Report 3Syringes and Needles Market Products Pipeline Review 2015 Report 4Syringes and Needles Market Products Pipeline Review 2015 Report 5
... CHICAGO, Nov. 10 Advanced Life Sciences Holdings, ... engaged in the discovery, development and commercialization of novel ... respiratory diseases, today announced its financial results for the ... (Logo: http://www.newscom.com/cgi-bin/prnh/20080218/ALSLOGO ) , The net loss ...
... NEW YORK, Nov. 10 Reportlinker.com announces ... available in its catalogue. , The ... Market Outlook , http://www.reportlinker.com/p0158356/The-Global-Drug-Delivery-Market-Research-Trends-and-Market-Outlook.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=prnewswire ... drug delivery industry has in recent years ...
Cached Medicine Technology:Advanced Life Sciences Announces Third Quarter 2009 Financial Results 2Advanced Life Sciences Announces Third Quarter 2009 Financial Results 3Advanced Life Sciences Announces Third Quarter 2009 Financial Results 4Advanced Life Sciences Announces Third Quarter 2009 Financial Results 5Advanced Life Sciences Announces Third Quarter 2009 Financial Results 6Advanced Life Sciences Announces Third Quarter 2009 Financial Results 7Advanced Life Sciences Announces Third Quarter 2009 Financial Results 8Advanced Life Sciences Announces Third Quarter 2009 Financial Results 9Advanced Life Sciences Announces Third Quarter 2009 Financial Results 10Reportlinker Adds The Global Drug Delivery Market: Research Trends and Market Outlook 2Reportlinker Adds The Global Drug Delivery Market: Research Trends and Market Outlook 3Reportlinker Adds The Global Drug Delivery Market: Research Trends and Market Outlook 4Reportlinker Adds The Global Drug Delivery Market: Research Trends and Market Outlook 5Reportlinker Adds The Global Drug Delivery Market: Research Trends and Market Outlook 6Reportlinker Adds The Global Drug Delivery Market: Research Trends and Market Outlook 7Reportlinker Adds The Global Drug Delivery Market: Research Trends and Market Outlook 8Reportlinker Adds The Global Drug Delivery Market: Research Trends and Market Outlook 9Reportlinker Adds The Global Drug Delivery Market: Research Trends and Market Outlook 10Reportlinker Adds The Global Drug Delivery Market: Research Trends and Market Outlook 11
(Date:8/3/2015)... Texas (PRWEB) , ... August 03, 2015 , ... ... an agreement to Seattle-based Genelex to offer pharmacogenetic lab testing and precision ... and reduce health care costs. , Annually, more than 8.6 million adverse ...
(Date:8/3/2015)... (PRWEB) , ... August 03, 2015 , ... Dental ... to help patients in need. Most people know that general health emergencies, such as ... a fewer amount of people know where to turn to during a dental emergency. ...
(Date:8/3/2015)... ... August 03, 2015 , ... ... ® and Navigant Center for Healthcare Research and Policy Analysis show widespread support ... of respondents said they agreed or strongly agreed that the controversial law passed ...
(Date:8/3/2015)... ... 2015 , ... The U.S. Food and Drug Administration (FDA) recently approved a ... acid, which occurs naturally in the body and helps absorb and breakdown fat cells. ... the body. These are invasive procedures and very expensive for most people. Now with ...
(Date:8/3/2015)... ... August 03, 2015 , ... Illinois Health & Science (IHS) has completed ... The acquisition includes all of IBAM NA’s cyclotron sites and research and development facilities. ... regionally located business, as well as a large manufacturing hub in Noblesville, Indiana,” said ...
Breaking Medicine News(10 mins):Health News:Novation Awards Genelex First Group Purchasing Agreement for Pharmacogenetic Testing and Precision Medicine Software 2Health News:Novation Awards Genelex First Group Purchasing Agreement for Pharmacogenetic Testing and Precision Medicine Software 3Health News:Los Angeles Dental Practice, Sunset Plaza Dental, Now Offers Emergency Dental Services 2Health News:Los Angeles Dental Practice, Sunset Plaza Dental, Now Offers Emergency Dental Services 3Health News:Survey Finds Support for the Affordable Care Act Among Physician Leaders 2Health News:Survey Finds Support for the Affordable Care Act Among Physician Leaders 3Health News:Dr. Ava Shamban to Offer the New Double Chin Treatment Kybella 2Health News:Dr. Ava Shamban to Offer the New Double Chin Treatment Kybella 3Health News:Illinois Health & Science Expands Nuclear Medicine Footprint With Purchase of IBA Molecular North America, Inc. 2
... of fathers in the United Kingdom appear to experience an ... of age, with the highest rates in the first year ... will appear in the November print issue of Archives ... journals. "Depression in parents is associated with adverse behavioral, ...
... HealthDay Reporter , FRIDAY, Sept. 3 (HealthDay News) -- ... lead to diabetes, a new study finds. Fish oil ... one of the most popular dietary supplements in the United ... beneficial, exactly how they work hasn,t been well understood, said ...
... Amanda Gardner HealthDay Reporter , FRIDAY, Sept. 3 ... in flophouses, theaters and high-end offices, bedbugs are popping up ... more places than just your bed. According ... 95 percent of U.S. pest management companies surveyed said they ...
... have found that people with Parkinson,s disease can perform ... have significant difficulty switching from easy to hard tasks. ... of the illness that affect the brain,s ability to ... Parkinson,s disease as being a disorder of motor function," ...
... large international study aimed at improving the care ... by physicians, physical therapists, and researchers at the ... "Berch" Griggs, M.D., is heading the study of ... form of the disease that affects children. The ...
... with advanced disease in palliative care settings receive oxygen therapy ... study from Duke University Medical Center says roughly half of ... do benefit, it doesn,t make a bit of difference whether ... both offer equal benefit. "Offering oxygen when patients ...
Cached Medicine News:Health News:Parents at highest risk for depression in the first year after child's birth 2Health News: Mouse Study May Help Explain Fish Oil's Benefits 2Health News: Mouse Study May Help Explain Fish Oil's Benefits 3Health News:Bedbug Nation: Critters Make a Comeback 2Health News:Bedbug Nation: Critters Make a Comeback 3Health News:Bedbug Nation: Critters Make a Comeback 4Health News:Rochester leads international effort to improve muscular dystrophy treatment 2Health News:Rochester leads international effort to improve muscular dystrophy treatment 3Health News:Rochester leads international effort to improve muscular dystrophy treatment 4Health News:Study challenges value of oxygen therapy in end-of-life care 2Health News:Study challenges value of oxygen therapy in end-of-life care 3
Versatility of the DFS Standard Fixator provides unsurpassed below-the-ring correction of angular, rotational and translational deformities. Length discrepancy can be precisely corrected in 1/4mm inc...
The PreFix™ temporary fixator prepares you for any situation that requires rapid stabilization of complex fractures....
Angulation, translation and rotation. A whole different point of view. The Sheffield Ring Fixation System is a design achievement that advances the possibilities of fracture management....
For radial/ulnar translation, angulation, dorsal/volar translation, and incremental longitudinal distraction, this advanced system is appropriate when incremental adjustment provides an adjunctive me...
Medicine Products: